Category - Markets

Cormark Securities initiated coverage on BioSyent (TSX-V: RX) with a “buy” recommendation and $10.25 target price. The stock closed at $8.40 on Thursday. BioSyent establishes and builds out pharmaceutical brands in the...

Leerink resumed coverage of Kura Oncology (NASDAQ:KURA) with an “outperform” rating and $15 price target. The stock closed at $5.60 on Wednesday. “We view Kura’s lead pipeline program, tipifarnib (a...

Stifel downgraded Alcobra (NASDAQ:ADHD) to “hold” from “buy” and slashed its price target to $3 from $17 after the FDA issued a clinical hold on the company’s Phase 3 study of metadoxine extended release (MDX) in adult...

JMP Securities resumed coverage of Cardiovascular Systems (NASDAQ:CSII) with a “market outperform” rating and $35 price target. The stock closed at $24.11 on Thursday. Cardiovascular is a medical technology company with...

RBC Capital Markets initiated coverage of CRH Medical (NYSE MKT:CRHM; TSX:CRH) with an “outperform” rating and price target of $6.50 (Canadian). The stock closed at $5.50 on Wednesday. Analyst Doug Miehm writes that CRH...

Roth Capital Partners downgraded iRadimed (NASDAQ:IRMD) to “neutral” from “buy” with a new price target of $11.50 after the company pre-announced a third quarter miss and reduced its 2016 outlook. The stock closed at...

Roth Capital Partners launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $15 price target. The stock closed at $7.74 on Friday. Sorrento has a proprietary fully human antibody library...

Roth Capital Partners initiated coverage of Fortress Biotech (NASDAQ:FBIO) with a “buy” rating and $9 price target. The stock closed at $2.97 on Friday. Fortress is dedicated to acquiring, developing and commercializing...

William Blair raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $12 from $9 after the company licensed exclusive worldwide rights to two preclinical cardiovascular programs to Amgen (NASDAQ:AMGN)...

Ladenburg Thalmann has initiated coverage of BioTime (NYSE MKT, TASE:BTX) with a “buy” rating and $6 price target. The stock closed at $3.59 on Thursday. “We view BioTime as roughly halfway through a restructuring...